Hims & Hers Secures $400M Financing Agreement with JPMorgan Chase
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 53 minutes ago
0mins
Source: stocktwits
- Financing Agreement Secured: Hims & Hers units XeCare and Apostrophe Pharmacy entered into a $400 million receivables purchase agreement with JPMorgan Chase, allowing the company to obtain immediate cash by selling customer receivables, thereby enhancing liquidity for its healthcare and pharmacy operations.
- Price Target Increases: Bank of America raised Hims' price target from $25 to $36 while maintaining a 'Neutral' rating, noting solid early traction for its branded GLP-1 products, although it remains to be seen if the company can sustain enough subscribers to support future EBITDA growth.
- Market Sentiment Shift: Retail sentiment for Hims on Stocktwits remains 'bearish', yet message volume surged by 177% in 24 hours, indicating increased investor interest and discussion regarding the company's new financing agreement, which may reflect a positive market reaction.
- FDA Regulatory Challenges: Hims' peptide products face FDA scrutiny, with analysts suggesting that the preliminary recommendation is not a final rejection, maintaining an optimistic outlook on future approvals, which could significantly impact the company's market prospects and investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to fall
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 34.670
Low
16.50
Averages
32.95
High
60.00
Current: 34.670
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. operates as a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims & Hers Secures $400M Financing Agreement with JPMorgan Chase
- Financing Agreement Secured: Hims & Hers units XeCare and Apostrophe Pharmacy entered into a $400 million receivables purchase agreement with JPMorgan Chase, allowing the company to obtain immediate cash by selling customer receivables, thereby enhancing liquidity for its healthcare and pharmacy operations.
- Price Target Increases: Bank of America raised Hims' price target from $25 to $36 while maintaining a 'Neutral' rating, noting solid early traction for its branded GLP-1 products, although it remains to be seen if the company can sustain enough subscribers to support future EBITDA growth.
- Market Sentiment Shift: Retail sentiment for Hims on Stocktwits remains 'bearish', yet message volume surged by 177% in 24 hours, indicating increased investor interest and discussion regarding the company's new financing agreement, which may reflect a positive market reaction.
- FDA Regulatory Challenges: Hims' peptide products face FDA scrutiny, with analysts suggesting that the preliminary recommendation is not a final rejection, maintaining an optimistic outlook on future approvals, which could significantly impact the company's market prospects and investor confidence.
See More
FDA Revives Advisory Committee Meetings for Drug Approvals
- Advisory Committee Revival: The FDA is reviving its Advisory Committee meetings under new leadership to reassess controversial decisions made during Marty Makary's tenure, which is expected to enhance the transparency and scientific rigor of drug approvals.
- Replimune and Capricor Reviews: Replimune (REPL) and Capricor Therapeutics (CAPR) are set for FDA advisory committee reviews at the end of July, with Replimune's RP1 targeting melanoma and Capricor's Deramiocel aimed at Duchenne muscular dystrophy, potentially impacting their market performance.
- Moderna Vaccine Endorsement: Moderna (MRNA) has received unanimous backing from the FDA's Vaccines Advisory Committee for its flu vaccine mRNA-1010, currently under review with a target action date of August 5, indicating strong competitive positioning in the vaccine market.
- Hims & Hers Market Potential: Hims & Hers Health (HIMS) is expected to benefit from an upcoming advisory committee meeting, which could allow it to capture one-fifth of the telehealth peptide market projected to reach $2.2 billion by 2027, although market performance remains uncertain.
See More
HIMS Faces Negative Impact from FDA's Peptide Recommendation
- FDA Recommendation Impact: HIMS is facing negative repercussions due to the FDA's recommendation against adding seven peptides to the bulk list, which will limit product diversity and potentially weaken market competitiveness, hindering future revenue growth.
- Market Reaction: The FDA's decision may adversely affect HIMS's peptide product line, raising investor concerns about the company's future profitability and potentially leading to stock price volatility.
- Analyst Rating Adjustment: Despite these challenges, BofA has raised HIMS's price target to $36, indicating confidence in the company's long-term potential, which may attract some investors to reassess their investment strategies.
- Strategic Adjustment Necessity: HIMS must reevaluate its product portfolio and market strategy in response to the FDA's restrictions to ensure sustained growth and innovation capabilities in a highly competitive market.
See More
FDA Challenges Seven Popular Peptides Amid Safety Concerns
- FDA Regulatory Challenge: FDA staff indicated insufficient evidence to support the compounding of seven peptides, including BPC-157 and Emideltide, citing unresolved safety concerns, which could impact Hims & Hers Health, Inc.'s market opportunities.
- Market Reaction: Hims' shares fell 0.3% following the FDA's announcement, despite a 33% increase in June, as investor uncertainty regarding peptide regulation raises concerns about future revenue streams.
- Industry Outlook: Hims acquired a California-based peptide manufacturing facility in early 2025 to enhance its domestic supply chain and support future work in preventive health and metabolic optimization, demonstrating the company's commitment to the peptide market.
- Analyst Perspective: Needham analyst Ryan MacDonald views the FDA's recommendation as not a final rejection, suggesting that while approval odds may be slightly lower, he still believes peptides could gain approval, potentially opening up billions in new revenue for Hims.
See More
Hims & Hers Health Inc. Stock Fluctuations
- Stock Performance: Hims & Hers Health Inc. closed at $33.39, reflecting a -1.62% decline from the previous day, underperforming against the S&P 500's gain of 1.18%, indicating market caution regarding its short-term outlook.
- Monthly Gain: The stock has risen by 29.79% over the past month, significantly outperforming the Medical sector's 7.96% increase, suggesting a relatively strong market position that may attract more investor interest.
- Earnings Expectations: The upcoming earnings report is expected to show an EPS of -$0.06, down 135.29% year-over-year, although quarterly revenue is projected at $689.49 million, up 26.55%, reflecting potential in revenue growth despite earnings challenges.
- Valuation Analysis: Hims & Hers currently trades at a forward P/E ratio of 646.48, substantially higher than the industry average of 27.78, indicating high market expectations for future growth but also raising concerns about its valuation sustainability.
See More
Restaurant Brands International Options Volume Surges
- Surge in Options Volume: Restaurant Brands International (QSR) has seen an options volume of 27,631 contracts today, equating to approximately 2.8 million shares, which represents a significant 76.2% of its average daily trading volume over the past month.
- High-Frequency Contracts: Notably, the $75 strike call option expiring on July 17, 2026, has traded 16,523 contracts today, representing about 1.7 million shares, indicating strong market interest at this price point.
- CAPR Options Activity: In parallel, Capricor Therapeutics (CAPR) has recorded an options volume of 7,668 contracts today, approximately 766,800 shares, which constitutes 75.2% of its average daily trading volume over the past month, highlighting investor attention on the company.
- Put Option Trading: The $20 strike put option expiring on August 21, 2026, has seen a trading volume of 5,735 contracts today, representing around 573,500 shares, reflecting a cautious market sentiment regarding CAPR's future performance.
See More
Hims & Hers Secures $400M Financing Agreement with JPMorgan Chase
- Financing Agreement Secured: Hims & Hers units XeCare and Apostrophe Pharmacy entered into a $400 million receivables purchase agreement with JPMorgan Chase, allowing the company to obtain immediate cash by selling customer receivables, thereby enhancing liquidity for its healthcare and pharmacy operations.
- Price Target Increases: Bank of America raised Hims' price target from $25 to $36 while maintaining a 'Neutral' rating, noting solid early traction for its branded GLP-1 products, although it remains to be seen if the company can sustain enough subscribers to support future EBITDA growth.
- Market Sentiment Shift: Retail sentiment for Hims on Stocktwits remains 'bearish', yet message volume surged by 177% in 24 hours, indicating increased investor interest and discussion regarding the company's new financing agreement, which may reflect a positive market reaction.
- FDA Regulatory Challenges: Hims' peptide products face FDA scrutiny, with analysts suggesting that the preliminary recommendation is not a final rejection, maintaining an optimistic outlook on future approvals, which could significantly impact the company's market prospects and investor confidence.
See More
FDA Revives Advisory Committee Meetings for Drug Approvals
- Advisory Committee Revival: The FDA is reviving its Advisory Committee meetings under new leadership to reassess controversial decisions made during Marty Makary's tenure, which is expected to enhance the transparency and scientific rigor of drug approvals.
- Replimune and Capricor Reviews: Replimune (REPL) and Capricor Therapeutics (CAPR) are set for FDA advisory committee reviews at the end of July, with Replimune's RP1 targeting melanoma and Capricor's Deramiocel aimed at Duchenne muscular dystrophy, potentially impacting their market performance.
- Moderna Vaccine Endorsement: Moderna (MRNA) has received unanimous backing from the FDA's Vaccines Advisory Committee for its flu vaccine mRNA-1010, currently under review with a target action date of August 5, indicating strong competitive positioning in the vaccine market.
- Hims & Hers Market Potential: Hims & Hers Health (HIMS) is expected to benefit from an upcoming advisory committee meeting, which could allow it to capture one-fifth of the telehealth peptide market projected to reach $2.2 billion by 2027, although market performance remains uncertain.
See More
HIMS Faces Negative Impact from FDA's Peptide Recommendation
- FDA Recommendation Impact: HIMS is facing negative repercussions due to the FDA's recommendation against adding seven peptides to the bulk list, which will limit product diversity and potentially weaken market competitiveness, hindering future revenue growth.
- Market Reaction: The FDA's decision may adversely affect HIMS's peptide product line, raising investor concerns about the company's future profitability and potentially leading to stock price volatility.
- Analyst Rating Adjustment: Despite these challenges, BofA has raised HIMS's price target to $36, indicating confidence in the company's long-term potential, which may attract some investors to reassess their investment strategies.
- Strategic Adjustment Necessity: HIMS must reevaluate its product portfolio and market strategy in response to the FDA's restrictions to ensure sustained growth and innovation capabilities in a highly competitive market.
See More
FDA Challenges Seven Popular Peptides Amid Safety Concerns
- FDA Regulatory Challenge: FDA staff indicated insufficient evidence to support the compounding of seven peptides, including BPC-157 and Emideltide, citing unresolved safety concerns, which could impact Hims & Hers Health, Inc.'s market opportunities.
- Market Reaction: Hims' shares fell 0.3% following the FDA's announcement, despite a 33% increase in June, as investor uncertainty regarding peptide regulation raises concerns about future revenue streams.
- Industry Outlook: Hims acquired a California-based peptide manufacturing facility in early 2025 to enhance its domestic supply chain and support future work in preventive health and metabolic optimization, demonstrating the company's commitment to the peptide market.
- Analyst Perspective: Needham analyst Ryan MacDonald views the FDA's recommendation as not a final rejection, suggesting that while approval odds may be slightly lower, he still believes peptides could gain approval, potentially opening up billions in new revenue for Hims.
See More
Hims & Hers Health Inc. Stock Fluctuations
- Stock Performance: Hims & Hers Health Inc. closed at $33.39, reflecting a -1.62% decline from the previous day, underperforming against the S&P 500's gain of 1.18%, indicating market caution regarding its short-term outlook.
- Monthly Gain: The stock has risen by 29.79% over the past month, significantly outperforming the Medical sector's 7.96% increase, suggesting a relatively strong market position that may attract more investor interest.
- Earnings Expectations: The upcoming earnings report is expected to show an EPS of -$0.06, down 135.29% year-over-year, although quarterly revenue is projected at $689.49 million, up 26.55%, reflecting potential in revenue growth despite earnings challenges.
- Valuation Analysis: Hims & Hers currently trades at a forward P/E ratio of 646.48, substantially higher than the industry average of 27.78, indicating high market expectations for future growth but also raising concerns about its valuation sustainability.
See More
Restaurant Brands International Options Volume Surges
- Surge in Options Volume: Restaurant Brands International (QSR) has seen an options volume of 27,631 contracts today, equating to approximately 2.8 million shares, which represents a significant 76.2% of its average daily trading volume over the past month.
- High-Frequency Contracts: Notably, the $75 strike call option expiring on July 17, 2026, has traded 16,523 contracts today, representing about 1.7 million shares, indicating strong market interest at this price point.
- CAPR Options Activity: In parallel, Capricor Therapeutics (CAPR) has recorded an options volume of 7,668 contracts today, approximately 766,800 shares, which constitutes 75.2% of its average daily trading volume over the past month, highlighting investor attention on the company.
- Put Option Trading: The $20 strike put option expiring on August 21, 2026, has seen a trading volume of 5,735 contracts today, representing around 573,500 shares, reflecting a cautious market sentiment regarding CAPR's future performance.
See More
